Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epstein-Barr virus envelope glycoprotein gp220 (None)
- Target
- None
- Molecular classification
- Viral envelope glycoprotein
01
Overview
Epstein-Barr virus (EBV) envelope glycoprotein gp220 is one of the two major outer envelope glycoproteins of EBV, along with gp350. Both proteins, often referred to as the "gp350/220" complex, are products of alternative splicing from the same primary RNA transcript and share significant sequence identity. Gp220 mediates high-affinity binding to complement receptor type 2 (CR2/CD21) on B lymphocytes, which is essential for EBV attachment and entry into B cells. This interaction is a major target for vaccine development and ligand-receptor blockade strategies.
- Other names
- gp220gp350/220
02
Mechanism of action
Ligand-receptor blockade
03
Biological functions
Viral attachmentViral entryB cell receptor bindingImmune evasion
04
Disease associations
InfectionEpstein-Barr virus infectionB cell lymphomasNasopharyngeal carcinomaInfectious mononucleosis
05
Safety considerations
Potential for off-target effects of antibodies targeting gp220/gp350Development of resistance to neutralizing antibodies
Beyond the preview
Go deeper on Epstein-Barr virus envelope glycoprotein gp220 (None).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epstein-Barr virus envelope glycoprotein gp220 (None).